share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

福泰製藥 | SC TO-T/A：發行招標公告
美股sec公告 ·  05/10 20:04
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced an amendment to its tender offer to acquire all outstanding shares of Alpine Immune Sciences, Inc. The offer, initially filed with the SEC on April 22, 2024, proposes a purchase price of $65.00 per share in cash. The tender offer is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. A key condition of the offer, the expiration of the waiting period under the HSR Act, was met on May 9, 2024, as both Vertex and Alpine filed their respective HSR Notification Forms with the FTC and the DOJ. The successful completion of this waiting period satisfies one of the conditions for the offer's consummation. The terms and conditions of the offer are detailed in the Offer to Purchase and the accompanying Letter of Transmittal, which are filed with the SEC. The amendment was signed by Jonathan Biller, Secretary of Adams Merger Sub, Inc., and Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated, on May 10, 2024.
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced an amendment to its tender offer to acquire all outstanding shares of Alpine Immune Sciences, Inc. The offer, initially filed with the SEC on April 22, 2024, proposes a purchase price of $65.00 per share in cash. The tender offer is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. A key condition of the offer, the expiration of the waiting period under the HSR Act, was met on May 9, 2024, as both Vertex and Alpine filed their respective HSR Notification Forms with the FTC and the DOJ. The successful completion of this waiting period satisfies one of the conditions for the offer's consummation. The terms and conditions of the offer are detailed in the Offer to Purchase and the accompanying Letter of Transmittal, which are filed with the SEC. The amendment was signed by Jonathan Biller, Secretary of Adams Merger Sub, Inc., and Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated, on May 10, 2024.
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc. 宣佈修訂其收購阿爾卑斯免疫科學公司所有已發行股份的要約。該要約最初於2024年4月22日向美國證券交易委員會提出，收購價爲每股65.00美元的現金。除非延期，否則要約將於美國東部時間2024年5月17日晚上 11:59 到期。該提議的一個關鍵條件，即《高鐵法》規定的等待期的到期，已於2024年5月9日得到滿足，因爲Vertex和Alpine都向聯邦貿易委員會和司法部提交了各自的高鐵通知表。成功完成這段等待期滿足了報價完成的條件之一。向美國證券交易委員會提交的收購要約和隨附的送文函中詳細介紹了要約的條款和條件。該修正案由亞當斯合併子公司秘書兼Vertex Pharmicals Incorporated執行副總裁兼首席法務官喬納森·比勒於2024年5月10日簽署。
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc. 宣佈修訂其收購阿爾卑斯免疫科學公司所有已發行股份的要約。該要約最初於2024年4月22日向美國證券交易委員會提出，收購價爲每股65.00美元的現金。除非延期，否則要約將於美國東部時間2024年5月17日晚上 11:59 到期。該提議的一個關鍵條件，即《高鐵法》規定的等待期的到期，已於2024年5月9日得到滿足，因爲Vertex和Alpine都向聯邦貿易委員會和司法部提交了各自的高鐵通知表。成功完成這段等待期滿足了報價完成的條件之一。向美國證券交易委員會提交的收購要約和隨附的送文函中詳細介紹了要約的條款和條件。該修正案由亞當斯合併子公司秘書兼Vertex Pharmicals Incorporated執行副總裁兼首席法務官喬納森·比勒於2024年5月10日簽署。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。